Pfizer Stock Rises on Upbeat RSV Vaccine Trial Data

A shift in sentiment could boost PFE stock

Fernanda Horner

Digital Content Manager

Apr 9, 2024 at 10:25 AM

Pfizer Inc (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher risk adults under the age of 60. The company plans to seek expanded approval of the vaccine for ages 18 to 59.

Shares are still struggling with resistance at the $29 level, which has been in place since January and rejected a mid-March rally off 11-year lows. In the last 12 months, PFE shed 35.3%.

Short-term options traders lean bearish. This is per PFE's Schaeffer's put/call open interest ratio (SOIR) of 1.05 that sits at the top percentile of annual readings. This means a shift in sentiment could generate tailwinds for Pfizer stock.

There's also room for optimism in the options pits. In fact, 11 of the 20 brokerage firms in question still rate the security a tepid "hold," while the remaining nine say "buy" or better.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.